ArticleAdvances in therapy2018

Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.

Miguel Salavert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.